Combination of | |
---|---|
Cefepime | cephalosporin |
Enmetazobactam | beta-lactamase inhibitor |
Clinical data | |
Trade names | Exblifep |
License data | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Cefepime/enmetazobactam, sold under the brand name Exblifep, is a medication used for the treatment of urinary tract infections. [1] [2] It is a fixed dose combination containing cefepime, a cephalosporin antibacterial, and enmetazobactam, a beta-lactamase inhibitor. [2]
The combination was approved for medical use in the United States in February 2024, [1] and in the European Union in March 2024. [2] [3] Enmetazobactam was first invented in India by Orchid Pharma and then out-licensed to Allecra Therapeutics for further development. [4]
In the US, cefepime/enmetazobactam is indicated for the treatment of people with complicated urinary tract infections including pyelonephritis, caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, and Enterobacter cloacae complex. [1]
In the EU, cefepime/enmetazobactam is indicated for the treatment of complicated urinary tract infections, including pyelonephritis; [2] hospital-acquired pneumonia, including ventilator-associated pneumonia; [2] and the treatment of people with bacteremia that occurs in association with, or is suspected to be associated with, any of the infections listed above. [2]
In January 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Exblifep, intended for the treatment of urinary tract infections and pneumonia in adults. [2] The applicant for this medicinal product is Advanz Pharma Limited. [2] The combination was approved for medical use in the European Union in March 2024. [2] [3]
Combination of | |
---|---|
Cefepime | cephalosporin |
Enmetazobactam | beta-lactamase inhibitor |
Clinical data | |
Trade names | Exblifep |
License data | |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
KEGG |
Cefepime/enmetazobactam, sold under the brand name Exblifep, is a medication used for the treatment of urinary tract infections. [1] [2] It is a fixed dose combination containing cefepime, a cephalosporin antibacterial, and enmetazobactam, a beta-lactamase inhibitor. [2]
The combination was approved for medical use in the United States in February 2024, [1] and in the European Union in March 2024. [2] [3] Enmetazobactam was first invented in India by Orchid Pharma and then out-licensed to Allecra Therapeutics for further development. [4]
In the US, cefepime/enmetazobactam is indicated for the treatment of people with complicated urinary tract infections including pyelonephritis, caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, and Enterobacter cloacae complex. [1]
In the EU, cefepime/enmetazobactam is indicated for the treatment of complicated urinary tract infections, including pyelonephritis; [2] hospital-acquired pneumonia, including ventilator-associated pneumonia; [2] and the treatment of people with bacteremia that occurs in association with, or is suspected to be associated with, any of the infections listed above. [2]
In January 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Exblifep, intended for the treatment of urinary tract infections and pneumonia in adults. [2] The applicant for this medicinal product is Advanz Pharma Limited. [2] The combination was approved for medical use in the European Union in March 2024. [2] [3]